SOURCE-LINKED STUDY SUMMARY
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Abstract summarizedQuality not appraised
- What was studied
- OASIS 1 tested daily oral semaglutide 50 mg plus lifestyle intervention against placebo plus lifestyle intervention for 68 weeks.
- Who / model studied
- The trial randomized 667 adults with overweight or obesity who did not have type 2 diabetes.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Estimated mean body weight changed by -15·1% with oral semaglutide versus -2·4% with placebo.
- Limitations & context
- Gastrointestinal adverse events occurred in 80% of semaglutide participants versus 46% with placebo. The trial population excluded people with type 2 diabetes.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(23)01185-6